rg1530
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00493155)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Multi-targeted kinase inhibitor
FLT3 inhibitor
Multi-targeted kinase inhibitor
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
Multi-targeted kinase inhibitor
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
Multi-targeted kinase inhibitor
PDGFRB inhibitor
Multi-targeted kinase inhibitor
AURKA inhibitor
Multi-targeted kinase inhibitor
- Serine/threonine-protein kinase PLK4INHIBITOR
PLK4 inhibitor
Multi-targeted kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2- Mol. weight
- 356.79 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1980391 ↗
Also known as
- 5-(2-chlorophenyl)-7-fluoro-1,2-dihydro-8-methoxy-3-methylpyrazol(3,4b)(1,4)benzodiazepine
- r 1530
- r-1530
- r-1530
- r-1530
- r1530 cpd
- rg1530
- rg-1530
- rg-1530
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00493155 | Phase 1 | Oct 1, 2005 | Roche |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 1 | 1 | 1 | 2005 |
1 organizations
Page 1 / 1